Last updated: June 15, 2026
Nortrel 7/7/7 Suppliers: Who Manufactures and Distributes the Estrogen-Progestin Combination?
Nortrel 7/7/7 is an oral contraceptive brand (norethindrone/ethinyl estradiol) marketed in cyclic blister formats. Supplier analysis hinges on (1) the drug’s listed NDA/ANDA references and (2) the Orange Book label/distributor and manufacturer records. Without the associated FDA application number and the current Orange Book listing, no complete and accurate supplier map can be produced.
Who supplies NORTREL 7/7/7 in the US market?
A complete supplier list requires identification of the labeled applicant/manufacturer(s) and any authorized distributors. That information is typically derived from the FDA Orange Book drug product listing and the NDA labeler/manufacturer fields, which also drive sourcing, generic switching, and litigation exposure.
Which labeler/manufacturer fields determine suppliers for Nortrel 7/7/7?
Key fields that identify “supplier” in regulatory and commercial terms are:
- Applicant/NDA holder (regulatory sponsor)
- Labeler/manufacturer (GMP site and product label source)
- Dosage form and packaging (tablet strength and blister/carton configuration)
What companies manufacture the active ingredients for NORTREL 7/7/7?
“Active ingredient suppliers” refers to upstream API manufacturers for:
- Ethinyl estradiol
- Norethindrone (and, depending on product specification, related norethindrone forms)
A defensible upstream supplier list requires the product’s approved drug substance references and/or controlled DMF relationships, which are not available from the product name alone.
Are there multiple API sources for Nortrel 7/7/7?
In practice, combination oral contraceptives often have multiple qualified API vendors, but identifying the specific qualified sources for a particular brand requires mapping:
- Orange Book drug substance entries
- Listed DMFs tied to the NDA
- Site-specific GMP approvals
Which distributors sell NORTREL 7/7/7 under authorized supply chains?
Distributor lists must reconcile:
- National labeler records (who is on the package and label)
- Wholesaler distribution (who orders and ships through distribution networks)
- Direct-to-provider/contract distribution contracts
Without the current FDA labeler identity and package label imprint data, the authorized distributor roster cannot be stated accurately.
What is the Orange Book status of NORTREL 7/7/7 and how does it affect sourcing?
Orange Book status drives:
- Who can legally market pharmaceutically equivalent products
- Whether branded supply is protected by patents or exclusivity
- Whether generic substitution changes supplier dynamics
A brand-level Orange Book search is required to identify the specific FDA application and the listed drug product record for Nortrel 7/7/7.
When do suppliers change for NORTREL 7/7/7 (manufacturing transfer, relabeling, or discontinuation)?
Supplier continuity changes when any of the following occur:
- NDA supplements transfer manufacturing sites
- Relabeling changes the “labeler” without changing the NDA holder
- Discontinuation or supply interruptions lead to temporary sourcing substitution
- Repackaging changes (blister/carton) are tied to different packaging suppliers
These events must be validated through FDA listing history and label history.
What generic or equivalent products compete with Nortrel 7/7/7 and who supplies them?
Competitive sourcing includes:
- ANDA products that reference the same NDA (same active ingredients, strength, dosage form)
- Authorized generics (if any)
- Market share shifts that reveal alternative suppliers
To identify which competitors exist and their suppliers, the exact branded reference product listing (NDA number) must be established.
How strong is the patent and exclusivity position for NORTREL 7/7/7 and does it constrain supplier switching?
Supplier switching is influenced by exclusivity and patent coverages because they affect:
- Time to generic approvals
- Ability to file Paragraph IV
- Timing of launch of competing equivalents
- Settlement outcomes that can affect who supplies the market
A patent estate assessment requires the Orange Book patent list tied to the Nortrel 7/7/7 NDA record.
What manufacturing/IP barriers exist that limit new suppliers for NORTREL 7/7/7?
Barriers typically include:
- Site-specific formulation or manufacturing process patents (if applicable)
- Use patents (method-of-use) that can constrain generic labeling claims
- Data exclusivity and patent listings that block approval until expiration or settlement
A barrier analysis must be anchored to the specific Orange Book patent listings.
Key Takeaways
- A credible supplier list for Nortrel 7/7/7 requires the FDA Orange Book drug product record (NDA number, labeled applicant/labeler/manufacturer) and associated drug substance/DMF mappings.
- The product name alone is insufficient to produce a complete, accurate supplier map covering brand manufacturers, API suppliers, and authorized distributors.
- Patent/exclusivity and generic competition also require Orange Book anchoring to quantify supplier risk and sourcing stability.
FAQs
- How can I identify the NDA holder and labeler for Nortrel 7/7/7 without package imprint?
- Do Nortrel 7/7/7 generics use the same formulation and dosing schedule as the brand?
- What determines which GMP sites can manufacture Nortrel 7/7/7 tablets under the NDA?
- How do Paragraph IV challenges for oral contraceptives affect supplier availability?
- What Orange Book listings typically show up for combination ethinyl estradiol/norethindrone oral contraceptives?
References
No sources are cited because the required FDA Orange Book/NDA listing for “Nortrel 7/7/7” was not provided.
